Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of elvitegravir to preparation of drugs for preventing or treating ALI/ARDS (acute lung injury/acute respiratory distress syndrome) and PF (pulmonary fibrosis)

A technology for acute respiratory distress and acute lung injury, which is applied in the application field of elvitegravir in the preparation of drugs for the prevention or treatment of acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis. And other issues

Inactive Publication Date: 2017-05-10
BINZHOU MEDICAL COLLEGE
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the pharmacological effects of evitagravir in the prevention or treatment of ALI / ARDS and pulmonary fibrosis have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of elvitegravir to preparation of drugs for preventing or treating ALI/ARDS (acute lung injury/acute respiratory distress syndrome) and PF (pulmonary fibrosis)
  • Application of elvitegravir to preparation of drugs for preventing or treating ALI/ARDS (acute lung injury/acute respiratory distress syndrome) and PF (pulmonary fibrosis)

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0010] Experimental Example 1 The effect of eptigovir on acute lung injury / acute respiratory distress syndrome (ALI / ARDS) model rats caused by cecal ligation and perforation

[0011] 1.1 Drugs and reagents

[0012] Etegavir (purity 99.5%, purchased from Shanghai Hanxiang Biotechnology Co., Ltd.)

[0013] Limulus Reagent Kit (Fuzhou Xinbei Biochemical Industry Co., Ltd., Fujian Province, batch number: 080430)

[0014] Anti-Aquaporin 5 antibody (abcam, ab104751)

[0015] Experimental animals: SPF-grade Sprague Dawley rats, male, weighing 150g-200g, provided by the Experimental Animal Center of Shandong Luye Pharmaceutical Co., Ltd., the animal certificate number is: SYXK (鲁)20030020.

[0016] 1.2 Experimental methods and results

[0017] 1.2.1 Preparation of cecal ligation and perforation (CLP) rats

[0018] In the early morning of the operation, the rats were fasted and placed supine after anesthesia with ether. The abdomen was disinfected with 75% ethanol. A 1.5cm incision was made along t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a new application of elvitegravir drugs and particularly relates to an application of elvitegravir to preparation of drugs for preventing or treating ALI / ARDS (acute lung injury / acute respiratory distress syndrome) and PF (pulmonary fibrosis). The use dosage of elvitegravir is 50-600 mg in the application.

Description

Technical field [0001] The present invention relates to eptegavir inhibiting the occurrence and development of acute lung injury / acute respiratory distress syndrome (ALI / ARDS) and pulmonary fibrosis, thereby preventing or treating ALI / ARDS and pulmonary fibrosis. Background technique [0002] Acute Lung Injury / Acute Respiratory Distress Syndrome (ALI / ARDS) is a common critical illness with a very high mortality rate, which seriously threatens the lives of critically ill patients and affects their quality of life. ALI / ARDS is the acute hypoxic respiratory function caused by the damage of lung capillary endothelial cells and alveolar epithelial cells in the process of non-cardiogenic diseases such as severe infection, shock, trauma and burns, resulting in diffuse pulmonary interstitial and alveolar edema. Insufficiency or failure, with reduced lung volume, reduced lung compliance, and severe ventilation / blood flow ratio imbalance are the pathophysiological characteristics. The cli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/47A61P11/00
CPCA61K31/47
Inventor 蒋王林张广华纪云霞李德芳吕长俊
Owner BINZHOU MEDICAL COLLEGE